Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mancuso

Showing results (131-140 of 219) with videos related to

Pageof 22
Sort By:
Scientific Reports|April 26, 2016
A comprehensive simulation framework for imaging single particles and biomolecules at the European X-ray Free-Electron LaserChun Hong Yoon, Mikhail V Yurkov, Evgeny A Schneidmiller, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markersF Bertolini, W Mingrone, A Alietti, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
Journal of Lipid Research|February 6, 2009
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolismMargaret E Brousseau, John S Millar, Margaret R Diffenderfer, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Leukemia|January 22, 2011
In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levelsE Belloni, D Shing, C Tapinassi, et al.
Diabetes, Obesity & Metabolism|September 2, 2024
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CVVikas S Sridhar, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Pageof 22

Showing results (131-140 of 219) with videos related to

Sort By:
Pageof 22
Scientific Reports|April 26, 2016
A comprehensive simulation framework for imaging single particles and biomolecules at the European X-ray Free-Electron LaserChun Hong Yoon, Mikhail V Yurkov, Evgeny A Schneidmiller, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markersF Bertolini, W Mingrone, A Alietti, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
Journal of Lipid Research|February 6, 2009
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolismMargaret E Brousseau, John S Millar, Margaret R Diffenderfer, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Leukemia|January 22, 2011
In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levelsE Belloni, D Shing, C Tapinassi, et al.
Diabetes, Obesity & Metabolism|September 2, 2024
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CVVikas S Sridhar, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Pageof 22